Zacks Investment Research upgraded shares of Sientra, Inc. (NASDAQ:SIEN) from a sell rating to a hold rating in a research note issued to investors on Wednesday, July 12th.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
A number of other equities research analysts have also recently issued reports on SIEN. ValuEngine upgraded shares of Sientra from a sell rating to a hold rating in a report on Thursday, June 22nd. Stephens started coverage on shares of Sientra in a report on Tuesday, July 11th. They set an overweight rating and a $12.00 price target for the company. Finally, Lake Street Capital started coverage on shares of Sientra in a report on Monday, April 17th. They set a buy rating and a $11.00 price target for the company.
Shares of Sientra (NASDAQ SIEN) traded down 1.45% on Wednesday, reaching $10.22. The company had a trading volume of 132,576 shares. The stock’s market capitalization is $195.53 million. The company has a 50 day moving average price of $10.43 and a 200 day moving average price of $8.93. Sientra has a 52-week low of $6.92 and a 52-week high of $11.47.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.04. The firm had revenue of $8.20 million during the quarter, compared to analysts’ expectations of $6.97 million. Sientra had a negative net margin of 173.83% and a negative return on equity of 48.02%. Sientra’s quarterly revenue was up 32.3% compared to the same quarter last year. On average, equities research analysts anticipate that Sientra will post ($2.31) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Sientra, Inc. (NASDAQ:SIEN) Upgraded by Zacks Investment Research to “Hold”” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/11/sientra-inc-nasdaqsien-raised-to-hold-at-zacks-investment-research-updated-updated-updated.html.
A number of large investors have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC boosted its stake in Sientra by 36.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,114,511 shares of the medical instruments supplier’s stock worth $10,833,000 after buying an additional 296,902 shares during the period. Schroder Investment Management Group boosted its stake in Sientra by 146.1% in the first quarter. Schroder Investment Management Group now owns 417,733 shares of the medical instruments supplier’s stock worth $3,442,000 after buying an additional 247,992 shares during the period. Northern Trust Corp boosted its stake in Sientra by 449.4% in the second quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock worth $1,451,000 after buying an additional 122,066 shares during the period. Morgan Stanley boosted its stake in Sientra by 449.6% in the first quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock worth $1,081,000 after buying an additional 105,005 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in Sientra by 18.0% in the first quarter. Ameriprise Financial Inc. now owns 659,859 shares of the medical instruments supplier’s stock valued at $5,555,000 after buying an additional 100,445 shares during the last quarter. Institutional investors own 77.80% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Sientra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sientra Inc. and related companies.